Literature DB >> 22955636

Retinal vasculitis in rheumatic diseases: an unseen burden.

Sofia Androudi1, Anna Dastiridou, Chrysanthos Symeonidis, Leila Kump, Anna Praidou, Periklis Brazitikos, Shree K Kurup.   

Abstract

Retinal vascular inflammation, a potentially blinding condition (herein: retinal vasculitis (RV)) is commonly associated with a heterogeneous group of diseases characterized by systemic inflammatory cell infiltration and/or necrosis of blood vessel walls. RV may arise as an isolated ocular disorder, as part of systemic vasculitis (Wegener's granulomatosis and Adamantiadis-Behcet Disease), or it can be secondary to an underlying connective tissue disease (systemic lupus erythematosus, sarcoidosis, and rheumatoid arthritis), systemic infection, or malignancy. Depending on the type of RV, it can be a potentially disabling condition, in the short or long term. Early diagnosis is the key to successful treatment and better prognosis. However, early diagnosis can be difficult, because these conditions usually present with nonspecific visual symptoms for a long period before diagnostic manifestations occur. The retina should be examined in warranted patients with verified rheumatic disease, since retinal vasculitis may be asymptomatic at the beginning (peripheral retinal disease). RV can be detected clinically (often accompanied by uveitis, scleritis, or macular edema) or revealed on fluorescein fundus angiography, even if minimal signs of retinal vessel inflammation are present. RV may also represent one of the possible extra-articular manifestations of the rheumatic disease. Rheumatologists should be familiar with the ocular manifestations of these disorders, since they may not only be sight-threatening, but more importantly, could be the presenting or even the very first manifestations of active, potentially lethal systemic disease in a patient with nonspecific rheumatologic presentation.

Entities:  

Mesh:

Year:  2012        PMID: 22955636     DOI: 10.1007/s10067-012-2078-1

Source DB:  PubMed          Journal:  Clin Rheumatol        ISSN: 0770-3198            Impact factor:   2.980


  45 in total

Review 1.  Vasculitis-aims of therapy. An overview.

Authors:  R A Watts; D G Scott; C D Pusey; C M Lockwood
Journal:  Rheumatology (Oxford)       Date:  2000-03       Impact factor: 7.580

Review 2.  Guidelines for the use of immunosuppressive drugs in patients with ocular inflammatory disorders: recommendations of an expert panel.

Authors:  D A Jabs; J T Rosenbaum; C S Foster; G N Holland; G J Jaffe; J S Louie; R B Nussenblatt; E R Stiehm; H Tessler; R N Van Gelder; S M Whitcup; D Yocum
Journal:  Am J Ophthalmol       Date:  2000-10       Impact factor: 5.258

3.  A diffuse disease of the peripheral circulation (usually associated with lupus erythematosus and endocarditis).

Authors:  G BAEHR; P KLEMPERER; A SCHIFRIN
Journal:  Am J Med       Date:  1952-11       Impact factor: 4.965

Review 4.  Current concepts in the etiology and treatment of Behçet disease.

Authors:  Cem Evereklioglu
Journal:  Surv Ophthalmol       Date:  2005 Jul-Aug       Impact factor: 6.048

5.  Disease relapse in patients with ocular manifestations of Wegener granulomatosis.

Authors:  W J Power; A Rodriguez; R A Neves; L Lane; C S Foster
Journal:  Ophthalmology       Date:  1995-01       Impact factor: 12.079

Review 6.  ANCA test in ophthalmic inflammatory disease.

Authors:  A H Kaufman; J L Niles; C S Foster
Journal:  Int Ophthalmol Clin       Date:  1994

7.  Systemic rheumatoid vasculitis: a clinical and laboratory study of 50 cases.

Authors:  D G Scott; P A Bacon; C R Tribe
Journal:  Medicine (Baltimore)       Date:  1981-07       Impact factor: 1.889

8.  Association of antiphospholipid antibodies with retinal vascular disease in systemic lupus erythematosus.

Authors:  A Montehermoso; R Cervera; J Font; M Ramos-Casals; M García-carrasco; F Formiga; J L Callejas; M Jorfán; M C Griñó; M Ingelmo
Journal:  Semin Arthritis Rheum       Date:  1999-04       Impact factor: 5.532

9.  Outcomes in anterior uveitis associated with the HLA-B27 haplotype.

Authors:  W J Power; A Rodriguez; M Pedroza-Seres; C S Foster
Journal:  Ophthalmology       Date:  1998-09       Impact factor: 12.079

10.  SLE retinopathy: evaluation by fluorescein angiography.

Authors:  J G Lanham; T Barrie; E M Kohner; G R Hughes
Journal:  Ann Rheum Dis       Date:  1982-10       Impact factor: 19.103

View more
  16 in total

1.  An assessment of ocular elasticity using real time ultrasound and ocular response analyzer in active or remission rheumatoid arthritis.

Authors:  Mehmet Erol Can; Özlem Unal; Meltem Ece Kars; Sukran Erten; Gamze Dereli Can; Necati Duru; Nurullah Cagil
Journal:  Int Ophthalmol       Date:  2018-12-03       Impact factor: 2.031

Review 2.  Ocular vasculitis.

Authors:  Gabriela M Espinoza; Ankit Desai; Levent Akduman
Journal:  Curr Rheumatol Rep       Date:  2013-09       Impact factor: 4.592

3.  Evaluation of retrobulbar blood flow and choroidal thickness in patients with rheumatoid arthritis.

Authors:  Ali Kal; Enes Duman; Almila Sarıgül Sezenöz; Mahmut Oğuz Ulusoy; Öznur Kal
Journal:  Int Ophthalmol       Date:  2017-07-20       Impact factor: 2.031

4.  The association of choroidal thickness with rheumatoid factor and anti-cyclic citrullinated peptide in rheumatoid arthritis.

Authors:  Arif Ülkü Yener; Kubilay Şahin
Journal:  Int Ophthalmol       Date:  2020-01-11       Impact factor: 2.031

5.  Uveitis in childhood-onset systemic lupus erythematosus patients: a multicenter survey.

Authors:  Paola Pinheiro Kahwage; Mariana Paes Leme Ferriani; João M Furtado; Luciana Martins de Carvalho; Gecilmara Salviato Pileggi; Francisco Hugo Rodrigues Gomes; Maria Teresa Terreri; Claudia Saad Magalhães; Rosa Maria Rodrigues Pereira; Silvana Brasilia Sacchetti; Roberto Marini; Eloisa Bonfá; Clovis Artur Silva; Virgínia Paes Leme Ferriani
Journal:  Clin Rheumatol       Date:  2017-01-09       Impact factor: 2.980

6.  Temporally independent association of multiple evanescent white dot syndrome and optic neuritis.

Authors:  Christopher D Conrady; Therese Sassalos; Wayne T Cornblath; David N Zacks; Mark W Johnson
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2021-05-29       Impact factor: 3.117

7.  [Structural and morphological changes in the eyes of arterial hypertensive patients with and without anti-CCP-positive rheumatoid arthritis].

Authors:  M Pahlitzsch; R Zielke; S Schlittgen; K Göbel; R Alten; C Erb
Journal:  Ophthalmologe       Date:  2017-04       Impact factor: 1.059

Review 8.  Extrapulmonary manifestations of sarcoidosis.

Authors:  Deepak A Rao; Paul F Dellaripa
Journal:  Rheum Dis Clin North Am       Date:  2013-03-13       Impact factor: 2.670

9.  Efficacy of adalimumab and infliximab in recalcitrant retinal vasculitis inadequately responsive to other immunomodulatory therapies.

Authors:  Claudia Fabiani; Jurgen Sota; Donato Rigante; Antonio Vitale; Giacomo Emmi; Giuseppe Lopalco; Lorenzo Vannozzi; Silvana Guerriero; Alice Bitossi; Ida Orlando; Rossella Franceschini; Bruno Frediani; Mauro Galeazzi; Florenzo Iannone; Gian Marco Tosi; Luca Cantarini
Journal:  Clin Rheumatol       Date:  2018-05-15       Impact factor: 2.980

10.  Impact of Sensory Impairments on Functional Disability in Adults With Arthritis.

Authors:  Diana E Fisher; Michael M Ward; Howard J Hoffman; Chuan-Ming Li; Mary Frances Cotch
Journal:  Am J Prev Med       Date:  2015-09-26       Impact factor: 5.043

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.